Introducing BluePrint™: A Molecular Subtyping Profile for Breast Cancer
As our understanding of the biology of breast cancer has advanced, so too has our ability to enhance treatment and patient outcomes as demonstrated by the increased survival of women with breast cancer over the past decade. While early detection and improved chemotherapy account for much of this progress, so also does a deeper understanding of the role of the estrogen and progesterone receptors and HER2 expression in our treatment strategies. Inherent is the recognition of the critical role of gene and protein expression of the breast cancer cell and our ability to characterize this in a way that clinicians can use to make treatment decisions. Routine immunohistochemistry has given way to ER, PR and HER2 measurement by single gene expression such as TargetPrint® and multi-gene expression assays such as MammaPrint® have evolved so that they have become part of routine decision-making for prognosis and prediction in the clinic worldwide. An additional level of understanding comes from recognition of the molecular subtypes of breast cancer, which further characterize tumors as Basal, Luminal or ERBB2 (HER2+) intrinsic subtypes.
Agendia developed BluePrint, a multi-gene profile, for the classification of breast cancer into Basal-type, Luminal-type and ERBB2-type (HER2/neu positive) molecular subclasses. Following risk assessment with a MammaPrint 'low risk' or 'high risk' result, additional stratification into a molecular subtype provides the next level of genomic breast cancer analysis.